TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00819910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Rosiglitazone 8mg daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone 8mg daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Rosiglitazone)
Description: Placebo (Rosiglitazone) 8mg daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Rosiglitazone)
Description: Placebo (Rosiglitazone) 8mg daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Fenofibrate)
Description: Placebo (Fenofibrate) 145 mg daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Fenofibrate)
Description: Placebo (Fenofibrate) 145 mg daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Fenofibrate 145 mg daily for 12 weeks
Study: NCT02052882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: romiplostim
Study: NCT02592655

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic Tourniquet
Description: Automated pneumatic tourniquet, applied to middle upper thigh.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: One Windlass Tourniquet
Description: One Windlass Tourniquet 3.8 cm (1.5 inch) wide. A Special Operations Forces Tactical Tourniquet Wide (SOFTT-W) will be used for the windlass tourniquet. One windlass tourniquet will be applied to the middle upper thigh.
Study: NCT00819910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 145 mg daily for 12 weeks
Study: NCT01821911

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zagreb2-1-1
Description: Injection on day 0、7、21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zagreb2-1-1
Description: Injection on day 0、7、21

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Essen
Description: Injection on day 0、3、7、14、28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Essen
Description: Injection on day 0、3、7、14、28
Study: NCT03547999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: The control arm (Arm A) and experimental arm (Arm B) will receive mFOLFOX6 every 2 weeks for 4 cycles. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: The control arm (Arm A) and experimental arm (Arm B) will receive mFOLFOX6 every 2 weeks for 4 cycles. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-CV301
Description: The experimental arm (Arm B) will receive MVA-BN-CV301 in 4 injections of 4 x 10(8) infectious units/0.5 mL given subcutaneously prior to the start of chemotherapy on days -28 and -14.
Study: NCT00291525

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-X Valve with Standard warfarin Therapy
Description: Valve replacement with standard dosage warfarin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-X Valve with Standard warfarin Therapy
Description: Valve replacement with standard dosage warfarin
Study: NCT03045822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bioimpedance analysis
Study: NCT02592655

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Two Windlass Tourniquets
Description: Two Windlass Tourniquets will be applied by applying a second 3.8 cm (1.5 inch) wide windlass tourniquet immediately proximal to the first windlass tourniquet.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet Tape 5 cm
Description: Tourniquet Tape is 5 cm (2 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet Tape 10 cm
Description: Tourniquet Tape is 10 cm (4 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
Study: NCT02913846

Intervention type: OTHER
Intervention: Nutritional evaluation
Description: A first nutritional evaluation will be performed within 48h of patient admission. Weight and BMI will be measured once a week.

Intervention type: OTHER
Intervention: Muscular assessment
Description: An assessment of muscular force will be performed once a week.

Intervention type: OTHER
Intervention: Pre-albumine dosage
Description: Dosage performed once a month.
Study: NCT03344887

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RBC Transfusion from male donor
Description: Patients requiring an RBC transfusion for the treatment of anemia will receive products from a male donor at initial and any subsequent hospitalizations during the trial period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RBC Transfusion from female donor
Description: Patients requiring an RBC transfusion for the treatment of anemia will receive products from a female donor at initial and any subsequent hospitalizations during the trial period.
Study: NCT03096431

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: * Self-exercise: number of steps per day, per fitness tracker; self-report of daily activity.~* One-to-one intervention: 30 minute sessions with licensed therapist to include warm-up, generalized strengthening, stretching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: * Self-exercise: number of steps per day, per fitness tracker; self-report of daily activity.~* One-to-one intervention: 30 minute sessions with licensed therapist to include warm-up, generalized strengthening, stretching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: * Self-exercise: number of steps per day, per fitness tracker; self-report of daily activity.~* One-to-one intervention: 30 minute sessions with licensed therapist to include warm-up, generalized strengthening, stretching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive rehabilitation
Description: One-to-one intervention: 45 minutes sessions with licensed therapist to include graded cognitive tasks designed to improve executive functioning with focus on both restorative and compensatory approaches.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive rehabilitation
Description: One-to-one intervention: 45 minutes sessions with licensed therapist to include graded cognitive tasks designed to improve executive functioning with focus on both restorative and compensatory approaches.
Study: NCT04379921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple Watch and App
Description: Participants in the Apple Watch and App arm will receive an Apple Watch and download an App (NeuroCoach). The Apple Watch and App are used for this study to record patient's mobility information (e.g., step counts, heart rate, stairs climbed, distance traveled) as well as provide an additional platform for patients to complete questionnaires.
Study: NCT01950520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propanolol 160mg, oral, by mouth (Cohort 1 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pindolol
Description: Pindolol 20mg, oral, by mouth (Cohort 1 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dantrolene
Description: Dantrolene 100mg, oral, by mouth (Cohort 1 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium Sulfate, infusion, 50 mg/kg bolus followed by maintenance infusion at 2g/h (Cohort 1 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine 200mg, oral, by mouth (Cohort 2 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qsymia
Description: Qsymia (topiramate 92mg CR, phentermine 15mg PO), oral, by mouth (Cohort 2 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate 200mg, oral, by mouth (Cohort 2 only)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Phentermine 37.5mg, oral, by mouth (Cohort 2 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone 100mg, oral, by mouth (Cohort 2 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50mg
Description: Mirabegron 50mg, oral, by mouth (Cohort 3 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 200mg
Description: Mirabegron 200mg, oral, by mouth (Cohort 3 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Cohort 1
Description: Placebo, oral, by mouth (Cohort 1 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Cohort 2
Description: Placebo, oral, by mouth (Cohort 2 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Mirabegron
Description: Placebo for Mirabegron, oral, by mouth (Cohort 3 only)
Study: NCT01896505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCP-330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCP-330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCP-330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCP-330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCP-330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCP-330
Study: NCT01134198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: Mifepristone 600mg, 3x/wk for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02503813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venous blood gas
Description: Venous blood gas will be measured at the time of arterial blood gas measurement.
Study: NCT04636541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: Goal Management Training® (GMT) has been developed to improve executive functions. It was validated in patients presenting executive dysfunction following many conditions: acquired traumatic brain injury, neurodevelopmental spina bifida, attention deficit and hyperactivity disorder (ADHD), subjective cognitive complaints and multiple sclerosis. GMT includes self-instruction strategies, self-monitoring exercises, cognitive training techniques, psychoeducation on cognitive processes, mindfulness exercises and assignments between sessions. It has been shown to increase patient awareness of deficits and improve cognitive control in goal-directed behaviors. The original GMT is a nine-week program administered to dysexecutive patients in 90-to-120-minute group sessions. Thus, it might be suitable for PD-MCI patients presenting with executive dysfunction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: See the Arm section for full details. For a justification of how we designed this intervention: Many clinical guidelines include general recommendations about giving information to PD patients and family so they can take part into decision process. However, few standardized psychoeducation interventions are available, and they don't include information on PD cognitive decline. Some studies investigated Mindfulness Based Stress Reduction (MBSR) and other related mindfulness interventions in PD patients. In this approach, formal meditative exercises are included to develop non-judgmental attention to experiences in the present moment. In elderly patients with MCI unrelated to PD, mindfulness interventions show positive effects on cognitive functioning, including attention, executive functioning and memory (Gard et al., 2014). Therefore, non-pharmacological interventions for PD-MCI including both education on cognitive symptoms, as well as mindfulness exercises, are promising.
Study: NCT03296813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Torsemide
Description: Loop diuretic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Loop diuretic
Study: NCT02672969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RapidVac Smoke Evacuator
Description: The intervention group, using the smoke evacuation (RapidVac Smoke Evacuator) in each OR, the data collection for the amount of surgical smoke and bio-aerosols' particles will be collected during pre-surgery and during surgery (every 30 mins).~Before using the smoke evacuation, the amount of surgical smoke and bio-aerosols' particles in the surgical field and OR environment will be measured by AeroTraxTM Handheld Airborne Particle Counter. This record includes the amount and size of smoke and bio-aerosol particles in each area such as anesthetic area (anesthesiologist physicians and nurses area); instrument preparation area (circulating nurses area) and surgical area (surgeons and scrub nurses areas).
Study: NCT02166801

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early intervention for infants
Description: Three foci are included in the intervention: Communication, Hand function and Mobility/gross motor function. The Hand \& Cognition and Mobility steps will be conducted during two time-periods. Communication will have a separate one-time intervention at the start of the study (prior to step I) in addition to one intervention period during step III (figure 1). General principles for the small step program: Training will be conducted in the children's home by the parents on a daily basis. The families will get instructions and supervision in their home every week by the therapist responsible for each specific step of the intervention. For each focus there will be different steps using an adaptive logarithm for training, i.e., adapted to the functional level of the child aiming at the next small developmental step. The family will be actively involved in identifying new foci for practice.
Study: NCT02234570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline administered with an oral dosing syringe. Group 1- Group 6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline administered with an oral dosing syringe. Group 1- Group 6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline administered with an oral dosing syringe. Group 1- Group 6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline administered with an oral dosing syringe. Group 1- Group 6
Study: NCT00997880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin calcium 40mg
Description: Rosuvastatin calcium 40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin calcium10mg
Description: Rosuvastatin 10mg
Study: NCT03270644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Administered orally
Study: NCT03547999

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPV-CV301
Description: The experimental arm (Arm B) will receive FPV-CV301 in 1 dose of 1 x 10(9) infectious units/0.5 mL given subcutaneously concurrently with chemotherapy (at least an hour prior to chemotherapy) on days 0, 14, 28 and 42 pre-operatively, and FVP-CV301 boosters on day 0 and 14 and then every 4 weeks (day 42, 70, 98). After day 98, FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab at a dose of 240 mg as a 30 minute IV infusion every 2 weeks until progression. Arm B will receive Nivolumab starting with the vaccinations. Arm A will begin the Nivolumab with the initiation mFOLFOX.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab at a dose of 240 mg as a 30 minute IV infusion every 2 weeks until progression. Arm B will receive Nivolumab starting with the vaccinations. Arm A will begin the Nivolumab with the initiation mFOLFOX.
Study: NCT03368534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous Regenerative Technology (ART)
Description: ART device with single-needle, fluid-assisted skin tissue harvesting technology.
Study: NCT00659048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Ciclesonide 200µg versus Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01825525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exposure to ScopeGuide
Description: The 2 minute protocol exposure to the electromagnetic field of the ScopeGuide device.
Study: NCT02540616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Electrical Stimulation
Description: A form of external neuromodulation using electrodes on the surface of the head. We will be using the TCT tDCS device (www.trans.cranial.com) or devices constructed by our research group or collaborators.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Electrical Stimulation
Description: A form of external neuromodulation using electrodes on the surface of the head. We will be using the TCT tDCS device (www.trans.cranial.com) or devices constructed by our research group or collaborators.
Study: NCT00836030

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study: NCT00478946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (FOLPI) Picoplatin with 5-FU and Leucovorin
Description: Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLPI
Description: Picoplatin, 150 mg/m2 to be administered with every alternate cycle of 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W, will be administered as a 2-hour infusion, either alone or, if the patient is to receive picoplatin that cycle, at the same time as picoplatin, in separate bags using a Y-line. The leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
Study: NCT01210131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]HX4
Description: Intravenous injection
Study: NCT03509883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Apixaban sprinkle capsules
Description: Single dose (25 x 0.1 mg capsules), oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Apixaban sprinkle capsules
Description: Single dose (25 x 0.1 mg capsules), oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Apixaban tablets followed by apixaban sprinkle capsules
Description: Apixaban sprinkle capsules Single dose (25 x 0.1 mg capsules), oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Apixaban tablets followed by apixaban sprinkle capsules
Description: Apixaban sprinkle capsules Single dose (25 x 0.1 mg capsules), oral administration
Study: NCT02785315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehabilitation & remediation approach
Description: The rehabilitation \& remediation approach group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention by discussing everyday situations with memory problem and specific strategies related to real-life situations. Investigators will also include one individual session in the 12 group sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: remediation approach
Description: The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
Study: NCT06228274

Intervention type: DEVICE
Intervention: ARTHRUM 2.5%
Description: ARTHRUM 2.5%
Study: NCT04212871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: watch food video 1
Description: A 2 minutes video, with food content. The first study used a ramen mukbang here, the second study used a hotpot mukbang.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: watch food video 2
Description: A 2 minutes video, with food content (different content from video 1). The first study used a donut mukbang here, the second study used a hotpot cooking show here.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: watch a non-food content video
Description: a 2 minutes video without food content. The first study used a documentary introducing the forbidden city, the second study used a documentary introducing Cornell University.
Study: NCT01890746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects \> 60 years: daunorubicin dose was adjusted to 60mg /m2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daunorubicin
Description: For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects \> 60 years: daunorubicin dose was adjusted to 60mg /m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m2/day continuous IV infusion on Days 1 through 7.
Study: NCT02575391

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole Food Intervention
Description: A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.